Cyto Pulse and the Center for Vaccine Development received IRB approval for a Phase I tolerability study of Easy Vax

GLEN BURNIE, Md.--(BUSINESS WIRE)--Cyto Pulse Sciences, a leading developer of tolerable, electric field based, intradermal and epidermal DNA vaccine delivery devices, today announced ethical committee approval for the Phase I medical device study to investigate the safety and tolerability of the Easy Vax™ Clinical Epidermal Electroporation System in healthy volunteers. The study, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be conducted by investigators at the Center for Vaccine Development, University of Maryland School of Medicine.

“This is another step in the development of our DNA vaccine delivery system, Easy Vax™”

“This is another step in the development of our DNA vaccine delivery system, Easy Vax™,” said Richard Walters, Cyto Pulse CEO. “The Easy Vax™ system is designed to be safe, effective for use in a broad range of environments and populations.”

“A major obstacle to the widespread use of DNA vaccines has been the availability of light-weight, portable and safe devices for vaccine delivery. DNA vaccines are well tolerated and can be readily manufactured at low cost for a wide variety of infectious diseases. This Phase I trial will allow us to test the safety and tolerability of the handheld, light-weight Easy Vax™,” said Samer El-Kamary, M.D., M.P.H., assistant professor of epidemiology and pediatrics at the University of Maryland School of Medicine and an associate member of its Center for Vaccine Development.

The Center for Vaccine Development was established in the 1970s and is one of the few university vaccine centers in the world engaged in the full range of vaccinology: from basic science through vaccine development, clinical evaluation and field studies.

Cyto Pulse Sciences, Inc. is a biomedical device and treatment development company commercializing technology to produce and deliver new medicine therapeutics (DNA/RNA) for: minimal residual disease cancer treatments (immunotherapy), protection against infectious diseases (prophylaxis therapy) and the correction of genetic defects (gene therapy). This innovative technology is used to discover and produce therapeutics such as monoclonal antibodies and polynucleotide vaccines and to deliver DNA and RNA vaccines. Additional information is available at the company's website, http://www.cytopulse.com.